Vaccine approaches for the ‘therapeutic management’ of *Mycobacterium avium* subspecies *paratuberculosis* infection in domestic livestock

Saurabh Gupta a, Shoor Vir Singh b, Manju Singh, Kundan Kumar Chaubey a, Kumaragurubaran Karthik b, A. K. Bhatia a, Naveen Kumar a and Kuldeep Dhamad a

aDepartment of Biotechnology, GLA University, Mathura, Uttar Pradesh, India; bCentral University Laboratory, Tamil Nadu Veterinary and Animal Sciences University, Chennai, Tamil Nadu, India; cVeterinary Type Culture Collection, NRC on Equines, Indian Council of Agricultural Research, Hisar, Haryana, India; dDivision of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh, India

ABSTRACT

High endemicity of Johne’s disease (JD) in herds adversely affects heavy milk yielding breeds by reducing the per animal productivity and ‘productive life-span’. This review evaluates different vaccines used for its control and summarizes the benefits of ‘global vaccine’ in the four major domestic livestock species, namely goat, sheep, buffalo and cattle. Vaccines developed by using ‘native strains’ revealed both ‘therapeutic’ and preventive effects in domestic livestock. The ‘therapeutic’ role of vaccine in animals suffering from clinical JD turned out to be valuable in some cases by reversing the disease process and animals returning back to health and production. Good herd management, improved hygiene, ‘test and cull’ methodology, proper disposal of animal excreta and monitoring of MAP bio-load were also regarded as crucial in the ‘therapeutic’ management of JD. Vaccine approaches have been widely adopted in JD control programs and may be considered as a valuable adjunct in order to utilize huge populations of otherwise un-productive livestock. It has been shown that vaccination was the preeminent strategy to control JD, because it yielded approximately 3–4 times better benefit-to-cost ratios than other strategies. Internationally, 146 vaccine trials/studies have been conducted in different countries for the control of JD and have shown remarkable reduction in its national prevalence. It is concluded that for JD, there cannot be global vaccines or diagnostic kits as solutions have to come from locally prevalent strains of MAP. Despite some limitations, vaccines might still be an effective strategy to reduce or eradicate JD.

1. Introduction

Johne’s disease (JD) caused by *Mycobacterium avium* subspecies *paratuberculosis* (MAP) affects domestic livestock population world-wide (Ayello et al. 2001; Chaubey et al. 2016). Bio-load of MAP in the Indian domestic livestock population has shown increasing trend in last 28 years (Singh et al. 2014a). Of the four domestic livestock species in India, bio-load of MAP has been reported to be highest (16.0–54.7%) in the sheep population, followed by 28.3–48.0% in buffaloes, 6.0–39.3% in cattle and 9.4–20.1% in goats (Kumar et al. 2008; Yadav et al. 2008; Sharma et al. 2008; Singh et al. 2014a; Mukartal et al. 2016).

Once this disease enters any herd it becomes established and endemic, since MAP is passed from one generation to another through semen, during pregnancy, by feeding of milk and colostrum and by oral-fecal route from contaminated environment (Buergelt et al. 2006; van Roermund et al. 2007; Eisenberg et al. 2010) and enters the human food chain leading to potential public health issues (Chaubey et al. 2017). In severely affected herds, losses are difficult to estimate since animals get culled early on health and production grounds from the elite germ-plasm developed through many years of genetic selection and breed improvement programs. Despite very high slaughter rate of domestic livestock (goats, sheep and buffaloes) to meet the ever growing demand of meat for domestic consumption and export, bio-incidence of JD continues to increase and has become endemic in several herds in the country. In addition, ‘test and cull’ is not an economically viable option for third world countries like India. Furthermore, ‘test and cull’ methodology has not yielded assured results in goats, though still practiced to reduce environmental contamination by removing shedding goats (Singh et al. 2014a). Similar findings have been reported in other parts of the world with respect to goats (Munir et al. 2014), buffaloes and cattle (Kirkeby et al. 2016; Konboon...
et al. 2018), where ‘test and cull’ methodology has been in use for long time but was found to be ineffective, therefore switched to vaccination for the control of the disease. Combined approaches using vaccination with ‘test and cull’ was far more economical and more effective strategy to control persistent losses and disease incidence in various herds of goats, buffaloes and cattle (Dorshorst et al. 2006; Kirkeby et al. 2016).

This review paper summarizes indigenous and global vaccines and vaccination approaches currently used in order to control JD with respect to improvements in the body condition, health, productivity and other parameters in the four major domestic livestock species, considering there is ban on cow slaughter in India.

1.1. Options for the control of JD

JD may be controlled by preventing newer cases of infections in calves or by eliminating source of infection, which can be achieved by identifying infected sub-clinical and clinical shedder animals and then either culling or segregating them from the healthy animals/stock (Kirkeby et al. 2016). In developing and poor countries where disease is highly endemic, it is not possible to indiscriminately cull large number of infected animals with high to very high level of infection (super shedders), primarily due to economic reasons. Therefore, it will be prudent to first focus on culling or segregation of super-shedders and then focus should be on resistant/resilient animals known to have received an infectious dose of MAP bacilli at an age when they were susceptible but not infected or remains in a dormant state so that when the animal is examined at necropsy, the infection cannot be detected by culture of tissues and there is no evidence of disease in the histopathological examination also (Whitlock et al. 2005; Whittington et al. 2017).

In view of the chronic and insidious nature of the disease, control programs can be time consuming and may take a minimum of 5 years or longer to be successful in controlling JD. Countries without paratuberculosis control practices of any kind are likely to suffer with greatest impact to human welfare through reduced production of animal protein and potential zoonotic impact. The practices and tools for the control of JD are well known and predominantly limited to breaking the transmission cycle. Culling (forced removal) of clinical cases, ‘test and cull’ approach for sub-clinical cases, hygienic rearing of young animals, bio-security measures and management of shed environment and pasture were leading approaches. Shed complexes and calving pens should be cleaned to reduce fecal contamination on the coats of animals. Weaning of the calves after colostrum feeding from JD-negative dams helps in reducing the risk of infection to new animals from infected parents. In already infected herds, manure management associated with feeding of colostrum or milk from JD-negative dams should get priority. Water should be piped and ponds and streams should be fenced to minimize fecal contamination of drinking troughs and grazing area may help to reduce losses due to JD (NADIS 2009). These precautions are not practiced and grossly over-looked in livestock farming in India, since majority of the livestock population of the country is in the hands of poor and marginal farmers. As a consequence, livestock frequently graze on public properties and is categorized as ‘zero-input agriculture’, with little or no attention on health care and lack of additional inputs in the form of green fodder and concentrates.

1.2. Test and cull methodology

MAP infection is predominantly prevented by closing new animal additions or securing additions or replacements from JD-free/negative herds (Kirkeby et al. 2016). Off-springs of positive cows are at risk for infection and should be either segregated or tested biannually in case of goats and sheep (Munir et al. 2014) and annually in case of cattle and buffaloes (Kirkeby et al. 2016; Konboon et al. 2018). For the elimination of JD, culling of daughters of sero-positive or culture-positive cows has been practiced in some of the developed countries. Annual testing of adult animals in herds is essential to identify and cull asymptomatic, sub-clinical and clinical shedders. Application of the diagnostic tests in the control programs has been critical for the chronic, insidious and spectral disease like JD, with focus on the presence and absence of bacilli and/or antibodies (Chaube et al. 2016). Though culture is more sensitive and considered ‘Gold standard’ test ELISA has been found to be quick and cost effective as screening test (Gupta et al. 2017). Problem with this approach is the long and variable time interval between the infection and time when the animals will either test positive or exhibit clinical symptoms (incubation), which in turn is dependent mainly on factors like management, nutrition, health care and other in-puts.

1.3. Vaccination strategy

Vaccination is the most efficient and cost-effective strategy for the prevention of appearance of the clinical cases in herds. Only seven countries have a control program in place that include vaccination. Major reason for not using vaccine is likely due to the interference of JD vaccines with serological tests for bovine tuberculosis (Coad et al. 2013; Serrano et al. 2017). Control of JD using vaccination, ‘test and cull’ or combined approaches was
economical and has been used as a tool to aid the control programs for JD in Australia, New Zealand, Spain, the Netherlands, Canada, Iceland and India (Basida and Juste 2011; Singh et al. 2015; Shephard 2014). However, vaccination has been prohibited in Denmark, Norway and Sweden and stamping out has been used as control practices instead. As an example, Australia used vaccine approach (5–35 years) to reduce infection from >35% to <1% (Hore et al. 1971; Dhand et al. 2016; Whittington et al. 2019). However, vaccination has been prohibited in Denmark, Norway and Sweden and stamping out has been used as control practices instead. As an example, Australia used vaccine approach (5–35 years) to reduce infection from >35% to <1% (Hore et al. 1971; Dhand et al. 2016; Whittington et al. 2019). Now USA is also adopting a mutant vaccine approach in controlling bovine JD. Control by vaccination provided minimal long-term losses with cost effective control over 10 year planning horizon (Lamont et al. 2014) (Table 1). In India, vaccination using ‘native strain’ administered to domestic livestock has improved per animal productivity and helped to conserve the threatened native breeds of domestic livestock, specially milk breeds due to JD in Indian conditions (Singh et al. 2017; Whittington et al. 2019). Now USA is also adopting a mutant vaccine approach in controlling bovine JD. Control by vaccination provided minimal long-term losses with cost effective control over 10 year planning horizon (Lamont et al. 2014) (Table 1). In India, vaccination using ‘native strain’ administered to domestic livestock has improved per animal productivity and helped to conserve the threatened native breeds of domestic livestock, specially milk breeds due to JD in Indian conditions (Singh et al. 2017; Whittington et al. 2019). Recently, ELISA-based tests (indigenous ELISA using whole cell proteolysis antigens and recombinant secretory proteins based cocktail ELISA) were developed Indigenousity to differentiate between infected and vaccinated animals (DIVA), since animals are not numbered in India and vaccine program may interfere in JD surveillance program (Chaubey et al. 2018).

Several other studies directed toward the development of subunit (such as immunogenic secretory proteins) or vectored vaccines (Faisal et al. 2013; Thakur et al. 2013; Gupta et al. 2016). Although these technologies are still under development and validation, they may provide effective vaccines in near future. Live vaccines may result in reduction of clinical disease in infected herds, but will not lead to eradication of infection. Immunity frequently breaks down when vaccinated animals are sold to other herds, negating the value of vaccination for herds selling breeding animals for replacements. As a result of this and because of vaccination with a live organism that may be capable of potentially infecting humans, therefore live vaccines are not favored by several countries (Park and Yoo 2016). Killed vaccines are preferably used and positive cost benefits have been reported with their use (Table 2). Currently there are limited number of killed vaccines licensed internationally against JD (Windsor 2006; Patton 2011; Singh et al. 2017).

Research into development of improved vaccines is being undertaken in many countries in the world. The main drawback to vaccination is that, since vaccines used in the field are not DIVA and can interfere with serological diagnosis of paratuberculosis and tuberculosis infections. There is also potential for interference with the skin test for tuberculosis. Tests capable of DIVA has been successfully developed and validated using field samples (Chaubey et al. 2018).

Over the period of few years, economic advantages of vaccination might be much higher than ‘test and cull’ strategy and combined approaches may be most effective in clinical shedders. Furthermore, it has been suggested that vaccination might be the beginning of the end of this devastating problem of domestic livestock world-wide known as ‘paratuberculosis’ and might mark the difference between doing nothing and advancing towards global control (Juste et al. 2002). An ideal JD vaccine should have following properties:

i. Ideal JD vaccine
   a. Cause minimal tissue injury.

---

Table 1. Transposon mutant vaccine candidates of MAP.

| Institution | Location of insertion | MAP strain | References |
|-------------|-----------------------|------------|------------|
| USDA-ARS-WRRC | MAP0482 | Goat strain 43432-02 | McGarvey, unpublished |
| University of Wisconsin | MAP0006c (lipH) | K-10 | Bannantine, 2014 |
| Washington State University | MAP1047 (relA) | K-10 | Park et al. 2014 |
| University of Nebraska | MAP1566 | K-10 | Rathnaiah et al. 2014 |
| University of Nebraska | MAP3695 and fadE5 | K-10 | Rathnaiah et al. 2014 |
| University of Nebraska | MAP0460 (lirZ) | K-10 | Rathnaiah et al. 2014 |
| University of Nebraska | MAP0282c and 0283c | K-10 | Rathnaiah et al. 2014 |
| University of Nebraska | MAP1566 | K-10 | Rathnaiah et al. 2014 |
| University of Nebraska | MAP2296c and 2297c | K-10 | Rathnaiah et al. 2014 |
| University of Nebraska | MAP1150c and 1151c | K-10 | Rathnaiah et al. 2014 |
| New York, USA | leuD | Strain 66115-98 | Faisal et al. 2013 |
| University of Wisconsin | MAP1872c (mtbH_2) | strain 989 | Kabara and Coussens, 2012 |
| AgResearch NZ | MAP1566 | K-10 | Scandurra et al. 2010 |
| AgResearch NZ | MAP0011 (ppiA) | K-10 | Scandurra et al. 2010 |
| Washington State University | MAP3893c (pknG) | K-10 | Park et al. 2011 |
| Washington State University | MAP0460 (lirZ) | K-10 | Park et al. 2011 |
| University of Wisconsin | MAP3963 | ATCC19698 | Shin et al. 2006 |
| University of Wisconsin | MAP2408c (fabG2_2) | ATCC19698 | Shin et al. 2006 |

*The location of the laboratory where the mutant(s) was constructed.
*The MAP locus where the transposon had been inserted. If two genes are listed, the transposon is inserted in the intergenic region between the two. If the gene has been named, it is shown in parenthesis.
*The parental strain of MAP used to create the mutation.
b. No interference between tuberculosis and paratuberculosis disease diagnosis.

c. Discriminate between infected and vaccinated animals against paratuberculosis.

d. Eliminate or reduce fecal shedding of bacteria.

Globally efforts are on to develop various type of vaccines with superior efficacy against JD of domestic livestock.

ii. JD vaccines under development globally.

a. Modified live attenuated whole cell MAP vaccines.

b. Gene knockout whole live MAP vaccines; live mutant vaccine: by random, direct and insertional mutagenesis.

c. Killed cell wall deficient (CWD) whole cell vaccines.

d. Vector-based vaccine: use of M. bovis BCG as vector to express MAP proteins.

e. Protein subunit vaccine MAP: recombinant MAP Hsp70, 74F, Ag85AA, g85BAg, 85C, SOD.

f. DNA vaccine: plasmid DNA encoding cocktail of MAP proteins.

In the global movement against JD, USA (bovine JD) besides Canada (Ovine JD) is latest to join and adopt vaccination program after the moderate success of ‘test and cull’ methodology. Control of disease using combined approach; of ‘test and cull’ and vaccination was more cost-effective than using ‘test and cull’ and/or vaccination. Internationally, 146 vaccine trials/studies have been widely conducted in different countries for the control of JD and have shown remarkable reduction in the National prevalence of JD (Whittington et al. 2019).

1.4. Monitoring parameters for ‘vaccination trials’

Vaccinated animals can be monitored for the response as per the methodology of Johne’s Disease Integrated Program (JDIP) of the USA with some modifications (Singh et al. 2007).

1.4.1. Herd profile

Age (6–12 months, 12–18 months and adult) and sex-wise (males/females) profile of the animals in the herds should be prepared. All the animals in a herd above 3 months of age were vaccinated with ‘vaccine’ as above, irrespective of sex, physical condition, physiological state and health condition (sub-clinical, clinical and advance clinical) with respect to MAP infection.

1.4.2. History of JD

Status of JD was estimated on the basis of history, mortality, morbidity, necropsy, screening of the farms, culling for JD disease infection, etc.

1.4.3. Screening of animals before vaccination

Fecal, serum, blood and milk samples were screened twice at monthly intervals using microscopy, culture, indigenous ELISA kit and IS900 PCR.

1.4.4. Monitoring of vaccinated animals

Vaccinated and control groups were monitored on following parameters from 0 to 360 days post vaccination on the basis of health (mortality, morbidity, etc.), body condition score and production parameters (birth weights, body weights gained, reproductive efficiency, etc.), physical condition (diarrhea, weakness, etc.), immunological parameters (ELISA titer or sero-conversion) and status of shedding of MAP. However, necropsy findings of animals died during the program was conducted and included. Tissues were examined for the presence and absence of gross and microscopic lesions of JD in visceral organs and particularly in mesenteric lymph nodes and intestinal mucosa.

**Table 2. Commercial Johne’s disease vaccines in the international market.**

| Sn | Name/kind of vaccine | Vaccine strain and bio-type | Adjuvants | Countries |
|----|----------------------|-----------------------------|-----------|-----------|
| 1  | Fromm                | MAP Strain 18, Killed       | Oil type (Freund’s complete) | USA       |
| 2  | Lio-Johns e           | 316F strain, Live attenuated | Oil type   | Spain     |
| 3  | Phylixia              | 5889 Bargey, Killed         | Oil type   | Hungary   |
| 4  | Weybridge Vaccine     | 316F strain, Live attenuated | Paraffin and olive oil with pumice stone powder | United Kingdom |
| 5  | Gudair® (Zoetis Pfizer) | MAP Strain 318F, Killed   | Oil emulsion | Australia |
| 6  | Aqua Vac Map          | Strain 316F, Live attenuated | Water based (saline) | New Zealand |
| 7  | Neoparasac (MerialNZ Ltd.)* | Freeze Dried Live MAP, Live attenuated | Oil type | France   |
| 8  | Mycopa®              | Whole cell bacterin, inactivated | Oil emulsion | Germany |
| 9  | Silirum (Pfizer CSL)  | MAP Strain 318F, Killed     | Oil emulsion | Australia |
| 10 | Bio-JD Oil & Gel (Biovet Pvt. Ltd)^b | Native MAP strain ‘S’ S ’Indian Bison type’, Inactivated | Aluminium hydroxide gel (Gudair, Spain), Gerbu adjuvant (Gerubibiotechnik, Germany) | India (2004–2014)* |

*aFor sheep and goats.
*bFor goats, sheep, cattle and buffaloes licensed by Drug Controller, Government of India (DCGI, New Delhi, license no. KTK/28D/11/2008) and candidate vaccine strain and technology has been transferred to M/S Biovetpvt. Ltd., Bengaluru, India.

In the global movement against JD, USA (bovine JD) besides Canada (Ovine JD) is latest to join and adopt vaccination program after the moderate success of ‘test and cull’ methodology. Control of disease using combined approach; of ‘test and cull’ and vaccination was more cost-effective than using ‘test and cull’ and/or vaccination. Internationally, 146 vaccine trials/studies have been widely conducted in different countries for the control of JD and have shown remarkable reduction in the National prevalence of JD (Whittington et al. 2019).
### 2. Comprehensive analysis of effects of JD vaccines world-wide

#### 2.1. Effects of vaccination on shedding of MAP bacilli

Screening of fecal samples at different time points (days post vaccination) showed that there was marked reduction (5.8–99.1%) in shedding of MAP bacilli in fecal samples (Table 3). Studies showed vaccination was the pre-eminent strategy to control JD, because it yielded approximately 3–4 times better benefit-to-cost ratios than other strategies (Park and Yoo 2016; Singh et al. 2017). Vaccination improved the immunity of individual animals and was able to arrest the progression of infection, which resulted in reduction of the shedding of bacilli.

#### 2.2. Effects of vaccination on production

Vaccine programs strongly suggested that vaccination in case of JD using vaccine developed from ‘native strain’ was more of a ‘therapeutic’ than ‘preventive’ effect, as confirmed by the positive results obtained by vaccinating infected adult animals (Singh et al. 2013; Juste and Perez 2011). Indian vaccination trials also confirmed ‘therapeutic nature’ of the ‘indigenous vaccine’ (Singh et al. 2010a, 2013, 2017). Vaccinations not only prevented development of sub-clinical cases into clinical cases but also cured infected adult animals and led to increased production at highly profitable benefit-to-cost ratio (Table 4).

#### 2.3. Effects of vaccination on histological lesions

Vaccination reverses the immuno-pathologic processes that led to the determined progressive intestinal inflammation responsible for clinical disease in such a way that immunized individuals were able to arrest the progression of infection and ensuing lesions. This resulted in the reduction of the excretion of MAP bacilli and significant decrease in the severity of clinical signs and economic losses (Table 5). According to the 1985 report, vaccination resulted in 98.0% reduction in postmortem finding of lesions, which during the period of 16 years, reduced incidence from 53.0% to 1.0% (Saxegaard and Fodstad 1985; Juste and Perez 2011). ‘Indigenous vaccine’ has been extensively applied in the 4 species of domestic livestock belonging to different breeds, locations and management conditions over period of past 10 years and has shown excellent performance. Vaccination of advance cases of animals suffering from JD infection have come back in to health and regained productive life (Singh et al. 2015; Singh et al. 2017).

#### 3. Next generation vaccines

Many efforts have been made to identify MAP antigens in development of subunit vaccines using genomic and proteomic analysis. Since the production of IFN-γ activated by Th1-mediated immune responses is critical in reducing the number of bacilli in early stages of MAP infection, identifying antigens that prompt strong Th1 responses is essential for the advancement of subunit vaccines (Rosseels and Huygen 2008).

Several antigens/proteins were tested for use as potential vaccine candidates: heat shock protein 70 (Hsp70) (Koets et al. 1999), antigen 85 complex proteins (Ag85A, Ag85B, and Ag85C) (Shin et al. 2005), lipoproteins (LprG and MAP0261c) (Huntley et al. 2005), superoxide dismutase (Shin et al. 2005) and alkyl hydroperoxide reductases (AhpC, AhpD) (Olsen et al. 2005). Study by Koets et al. (2006) reported that Hsp70 has been widely used as a subunit vaccine candidate and vaccination using Hsp70 minimize

### Table 3. Effects of vaccination on shedding of MAP bacilli (globally).

| Sn  | Name/kind of vaccine          | Country | Species (breed) | Reduction (%) | Period of study | References                  |
|-----|------------------------------|---------|-----------------|---------------|-----------------|----------------------------|
| 1.  | Laboratory Scale (Live) USA  | Cattle  | 81.4            | -             | Larsen et al. 1974 |
| 2.  | Fromm (Killed) USA           | Cattle  | 99.0            | -             | Hurley et al. 1983 |
| 3.  | Live attenuated USA          | Cattle  | 90.0            | -             | Saxegaard & Fodstad, 1985 |
| 4.  | Laboratory Scale (Live) Denmark | Cattle  | 92.9            | -             | Jorgensen, 1983   |
| 5.  | Laboratory Scale (Live)      | France  | 81.6            | 5 years       | Argente, 1992    |
| 6.  | Phylaxia (Killed) Hungary    | Cattle  | 94.7            | -             | Kormendy, 1994   |
| 7.  | Neoparasec (Live) Germany    | Cattle  | 86.8            | -             | Klawonnet al. 2002 |
| 8.  | Lio-Johne (Live) Spain       | Sheep   | 80.8            | -             | Aduriz, 1993     |
| 9.  | Laboratory Scale (Live) Greece | Sheep   | 93.2            | -             | Dimarelli-Malli et al. 1997 |
| 10. | Gudair (Killed) Australia    | Australia | 90.0      | -             | Eppler et al. 2004 |
| 11. | Laboratory Scale (In-activated) India | Goat (Barbari) | 82.1 | - | Singh et al. 2007 |
| 12. | Laboratory Scale (In-activated) India | Goat (Barbari type) | 62.1 | 7 months | Singh et al. 2010a |
| 13. | Laboratory Scale (In-activated) India | Goat (Jamunapari) | 26.8 | 7 months | Singh et al. 2013 |
| 14. | Laboratory Scale (In-activated) India | Sheep (Bharat Merino) | 27.3 | 3 years | Singh et al. 2013a |
| 15. | Laboratory Scale (In-activated) India | Sheep (Patanwadi) | 17.1 | 4 months | Shroff et al. 2013 |
| 16. | Laboratory Scale (In-activated) India | Goat (Mehsana) | 5.8 | 4 months | Singh et al. 2013b |
| 17. | Laboratory Scale (In-activated) India | Cattle (H/F2) | 46.6 | 6 months | Rawat et al. 2014 |
| 18. | Commercial Scale (In-activated) India | Cattle (Hariana type) | 89.3 | 9 months | Singh et al. 2015 |
| 19. | Commercial Scale (In-activated) India | Goat (Jakhkana) | 45.5 | 12 months | Singh et al. 2017 |

*Indigenous vaccine is now commercialized.

†Holstein Friesian breed.
secretory proteins from native Rinjardin 1926. Since then, a number of whole-cell and oil-based adjuvant was developed by Vallee and First MAP vaccine consisted of live non-virulent MAP. Recently, Gupta et al. 2019 evaluated in mouse models. Recently, Gupta et al. 2019 experimentally challenged with MAP. While bacterial load as compared with non-vaccinated cattle experimentally challenged with MAP.

Several candidates were evaluated for their ability to induce protective immune responses. However, they were only evaluated in mouse models. Recently, Gupta et al. 2016 have identified 14 immunogenic natural secretory proteins from native ‘S 5’ strain of MAP ‘Indian Bison type’ biotype prevalent in Indian domestic livestock and human population. Diagnostic potential of natural and recombinant immunogenic secretory proteins were evaluated by ‘indirect ELISA’ and working well in diagnosing the active infection of MAP (Chaubey et al. 2018) and will be good candidates to be used as ‘vaccine candidates in future.Recently, to improve the competence of the MAP live attenuated vaccines, JDIP research consortium established a three-phase vaccine candidate evaluation method (Bannantine et al. 2014). First phase, a screening test using in vitro bovine monocyte-derived macrophage model was conducted by Lamont et al. (2014) to evaluate many live attenuated vaccine candidates constructed until 2014, second phase was a challenge test using the mouse model, and third phase was assessment of protective effects using goat model.

### 4. Commercially available vaccines and future scope

First MAP vaccine consisted of live non-virulent MAP and oil-based adjuvant was developed by Vallee and Rinjardin 1926. Since then, a number of whole-cell killed vaccines, live attenuated and inactivated vaccines were developed to prevent bovine, ovine and caprine JD. Currently, three commercial vaccines (whole cell killed) viz., Mycopar®, Gudair® and Silirum® are available (Bastida and Juste 2011). Mycopar® is the only approved vaccine manufactured using MAP ‘strain 18’ (member of the family of Mycobacterium avium subspecies paratuberculosis) against bovine JD in the USA (Patton 2011). Gudair® is manufactured by Zoetis (formerly by CZ Veterinaria in Spain) using heat inactivated MAP ‘316F’ strain adjuvanted with mineral oil used in Australia for the control of ovine JD (Windsor 2006). An Australian study opined reduction in the prevalence of MAP shedding after vaccination with their longitudinal study (Eppleston et al. 2005). However, a cross-sectional study by Windsor in 2014 revealed that shedding of MAP persisted in the majority of herds, despite vaccination of lambs. Silirum® consists of MAP ‘316F’, similar to Gudair® and is manufactured by Zoetis AU to prevent bovine JD. Effectiveness of Silirum® vaccine was studied in young farmed deer in New Zealand which revealed that vaccination has reduced the prevalence of clinical JD (Stringer et al. 2013).

Regardless of the advantages of vaccination, one major drawback of ‘whole-cell killed’ vaccine is interference with diagnostic tests currently used in bovine tuberculosis and paratuberculosis (Kohler et al. 2001; Musken et al. 2002). Therefore, current research focused towards the development of DIVA...

---

**Table 4. Effects of vaccination on production parameters (mortality or clinical cases).**

| Sn | Name/kind of vaccine | Country | Species (breed) | Reduction (%) | Period of study | Reference |
|----|----------------------|---------|-----------------|---------------|----------------|-----------|
| 1. | Weybridge (Live)     | UK      | Cattle          | 99.06         | –              | Wilesmith, 1982 |
| 2. | Lelystad (Killed)    | The Netherlands | Cattle | 91.82         | –              | Kallsen, 1992 |
| 3. | Lio-Johne (Live)     | Spain   | Sheep           | 78.29         | –              | Aduriz, 1993 |
| 4. | Gudair (Killed)      | Australia | Sheep | 87.5          | –              | Windsor et al. 2003 |
| 5. | Neoparasac (Live)    | New Zealand | Sheep | 71.43         | One year       | Gwozdz et al. 2000 |
| 6. | Laboratory Scale (Live) | Greece | Goat           | 82.78         | –              | Xenoset al. 1988 |
| 7. | Laboratory Scale (In-activated) | India | Goat (Barbari type) | 54.8          | 7 months       | Singh et al. 2010a |
| 8. | Laboratory Scale (In-activated) | India | Goat (Janunapari) | 24.6          | 7 months       | Singh et al. 2013 |
| 9. | Laboratory Scale (In-activated) | India | Goat (Mehsana) | 40.0          | 4 months       | Singh et al. 2013b |
| 10. | Laboratory Scale (In-activated) | India | Cattle (H/F) | 95.0          | 6 months       | Rawat et al. 2014 |
| 11. | Commercial Scale (In-activated) | India | Goat (Jahranra) | 53.8          | 12 months      | Singh et al. 2017 |

*Indigenous vaccine is now commercialized.
Holstein Friesian breed.

**Table 5. Effects of vaccination on histological lesions (globally).**

| Sn | Name/kind of vaccine | Country | Species (breed) | Reduction (%) | Period of study | Reference |
|----|----------------------|---------|-----------------|---------------|----------------|-----------|
| 1. | Laboratory Scale (Killed) | The Netherlands | Cattle | 58.9          | 12 years       | van Schalk et al. 1996 |
| 2. | Silirum (Killed) | Spain | Cattle | 38.6          | –              | Garcia-Pariente et al. 2005 |
| 3. | Laboratory Scale (Killed) | Iceland | Sheep | 93.5          | –              | Sigurdsson, |
| 4. | Lio-Johne (Live) | Spain | Sheep | 100.0         | –              | Aduriz, 1993 |
| 5. | Mycopar (Killed) | USA | Sheep | 75.3          | –              | Thonney and Smith, 2005 |
| 6. | Gudair (Killed) | Australia | Sheep | 72.7          | 5 years       | Reddcliff et al. 2006 |
| 7. | Gudair (Killed) | New Zealand | Sheep | 75.5          | 16 months     | Griffin et al. 2009 |
| 8. | Laboratory Scale (Live) | Norway | Goat | 97.1          | 14 years      | Saxegaard and Fostad, 1985 |
| 9. | Gudair (Killed) | Spain | Goat | 65.8          | –              | Copra et al. 2000 |
| 10. | Laboratory Scale (In-activated) | USA | Goat | 66.6          | ~9 months     | Kathaperumal et al. 2009 |
| 11. | Laboratory Scale (In-activated) | India | Goat (Barbari) | 75.0          | –              | Singh et al. 2007 |
| 12. | Laboratory Scale (In-activated) | India | Goat (Barbari) | 57.1          | 7 months       | Singh et al. 2010a |
| 13. | Commercial Scale (In-activated) | India | Goat (Hannana type) | 65.7          | 4 months       | Singh et al. 2015 |

*Indigenous vaccine is now commercialized.
test to DIVA (Jayaraman et al. 2016; Chaubey et al. 2018). These vaccines have the potential to produce false positive results in serological tests for paratuberculosis such as ELISA because the commercial ELISA kit consisted of crude MAP antigens, which hinder DIVA (Santema et al. 2011). However, in the IFN-γ assay, stimulation with MAP PPD-B produced strong responses similar to MAP PPD-J (purified protein derivatives) in MAP vaccinated animals (Muskens et al. 2002; Stabel et al. 2011). Because of this cross-reaction with other mycobacteria many countries that are running M. bovis eradication programs do not use vaccination policies. However, these problems can be overcome by development of new diagnostic assays using immunogenic natural or recombinant secretory proteins as ‘vaccine candidates’ (Gupta et al. 2016). Another drawback of whole cell killed vaccines is the substantial tissue damage at the injection site and accidental self-inoculation, which may cause serious side-effects (Patterson et al. 1988). However, there is a vaccine adjuvanted with highly refined mineral oils such as Silurium® to decrease the formation of granuloma at the site of injection (Rosseels and Huygen 2008).

Therefore, major recommendation which comes from this review is that for a chronic and insidious infection like JD, there cannot be global ‘vaccines’ or ‘diagnostic kits’, the solutions have to come from local ‘pathogenic bio-types’/strains of MAP prevalent in particular species of livestock and regions/agro-climatic zones.

5. Conclusion

Vaccines against paratuberculosis have been developed by diverse approaches. Most important factors to consider in ‘vaccine studies’ are the mechanisms related to the host-pathogen interactions and the ‘vaccine biotype’ used. Much more efforts are needed to understand exactly how bacteria can evade the host defense system, and these should focus on not only an adaptive immune system but also innate immunity. Vaccines that can induce both cellular and humoral immune responses may have improved protective effects. Using local or indigenous strains provide better ‘protective index’ as compared to vaccines based on foreign strains. Despite some limitations with particular vaccine candidates, vaccines are the most ‘effective strategy’ to reduce or control or eradicate JD in livestock herds globally. Disease being highly endemic in developing and less developed countries, as suggested by low per animal productivity and in view of the limitations of resources, vaccines are the only cost effective methodology for the management of ‘incurable’ JD at country/regional level.

Disclosure statement

No potential conflict of interest was reported by the authors.

ORCID

Shoor Vir Singha http://orcid.org/0000-0001-9619-7597
Kundan Kumar Chaubeyb http://orcid.org/0000-0002-5940-4638
Kumaragurubaran Karthick http://orcid.org/0000-0002-9215-6306
Kuldeep Dhama http://orcid.org/0000-0001-7469-4752

References

Aduriz JJ. 1993. Epidemiologia, diagnostico y control de la paratuberculosis ovina en la Comunidad Autonoma del Pais Vasco. Spain: University of Zaragoza.

Argente G. 1992. Efficiency of vaccination and other control measures estimated by fecal culturing in a regional program. In: Chiodini RJ, Kreegel JM, editors. Proceedings of the 3rd International Colloquium on Paratuberculosis; Orlando, Florida, USA: International Association for Paratuberculosis. p. 495–503.

Ayele WY, Machackova M, Pavlik I. 2001. The transmission and impact of paratuberculosis infection in domestic and wild ruminants. Vet Med. 46(No. 7–8):205–222.

Bannantine JP, Hines ME, 2nd, Bermudez LE, Talata AM, Sreevatsan S, Stabel JR, Chang YF, Coussens PM, Barletta RG, Davis WC, et al. 2014. A rational framework for evaluating the next generation of vaccines against Mycobacterium avium subspecies paratuberculosis. Front Cell Infect Microbiol. 4:126.

Bastida F, Juste RA. 2011. Paratuberculosis control: a review with a focus on vaccination. J Immune Based Ther Vaccines. 9:8

Buergelt CD, Williams BS, Monif GRG, Pinedo P, Decker JH. 2006. Nested polymerase chain reaction and prenatal detection of Mycobacterium avium subspecies paratuberculosis (MAP) in bovine allantoic fluid and fetuses. Int J Appl Res Vet Med. 4:232–240.

Chaubey KK, Gupta RD, Gupta S, Singh SV, Bhatia AK, Jayaraman S, Kumar N, Goel A, Rathore AS, Sahzad, Sohal JS, et al. 2016. Trends and advances in the diagnosis and control of paratuberculosis in domestic livestock. Vet Q. 36:203–227.

Chaubey KK, Singh SV, Bhatia AK. 2018. Evaluation of ‘Recombinant secretary antigens’ based ‘Cocktail ELISA’ for the diagnosis of Johne’s disease and to differentiate non-infected, infected and vaccinated goats in combination with indigenous ELISA test. Small Rumin Res. 165:24–29.

Chaubey KK, Singh SV, Gupta S, Singh M, Sohal JS, Kumar N, Singh MK, Bhatia AK, Dharma K. 2017. Mycobacterium avium subspecies paratuberculosis – an important food borne pathogen of high public health significance with special reference to India: an update. Vet Q. 37(1):282–299.

Coad M, Clifford DJ, Vordermeier HM, Whelan AO. 2013. The consequences of vaccination with the Johne’s disease vaccine, Gudair, on diagnosis of bovine tuberculosis. Vet Rec. 172(10):266.

Corpa JM, Peerez V, Garcia Marin JF. 2000. Differences in the immune responses in lambs and kids vaccinated
against paratuberculosis, according to the age of vaccination. Vet Microbiol. 773(3-4):475.

Dhand NK, Eppleston J, Whittington RJ, Windsor PA. 2016. Changes in prevalence of ovine paratuberculosis following vaccination with Gudair®: results of a longitudinal study conducted over a decade. Vaccine. 34(42):5107–5113.

Dimareli-Malli Z, Sarris K, Papadopoulos O, N I, Xenos G, A M, Papadopoulos G. 1997. Evaluation of an inactivated whole cell experimental vaccine against paratuberculosis in sheep and goats. PTBC Newsletter. 9:10–17.

Dorshorst NC, Collins MT, Lombard JE. 2006. Decision analysis model for paratuberculosis control in commercial dairy herds. Prev Vet Med. 75(1-2):92–122.

Eisenberg SW, Koets AP, Hoeboer J, Bouman M, Heederik D, Nielen M. 2010. Presence of Mycobacterium avium subsp. paratuberculosis in environmental samples collected on commercial Dutch dairy farms. Appl Environ Microbiol. 76(18):6310–6312.

Eppleston J, Reddactliff L, Windsor P, Links I, Whittington R. 2005. Preliminary observations on the prevalence of sheep shedding Mycobacterium avium subsp. paratuberculosis after 3 years of a vaccination program for ovine Johne’s disease. Australian Vet J. 83(10):637–638.

Eppleston J, Reddactliff L, Windsor P, Whittington R, Jonbes S. 2004. Field studies on vaccination for the control of OJD in Australia - and overview. Proc Aust Sheep Vet Soc. 56–59.

Faisal SM, Yan F, Chen T-T, Useh NM, Guo S, Yan W, Wang S-J, Glaser AL, McDonough SP, Singh B, Chang Y-F. 2013. Evaluation of a Salmonella vectored vaccine expressing Mycobacterium avium subsp. paratuberculosis antigens against challenge in a Goat Model. PLoS ONE. 8(8):e70171.

Garcia-Pariente C, Perez V, Geijo M, Moreno O, Munoz M, Fuentes M, Puentes E, Doce J, Ferreras MC, Garcia Marin JF, 2005. The efficacy of a killed vaccine against paratuberculosis (SILRUM®) in cattle. A field study. In: Manning EJB, Nielsen SS, editors. Proceedings of the 8th International Colloquium on Paratuberculosis; Copenhagen, Denmark: International Association for Paratuberculosis. p. 52.

Griffin JF, Hughes AD, Liggett S, Farquhar PA, Mackintosh CG, Bakker D. 2009. Efficacy of novel lipid-formulated whole bacterial cell vaccines against Mycobacterium avium subsp. paratuberculosis in sheep. Vaccine. 27(6):911–918.

Gupta S, Singh SV, Bhatia AK. 2017. Revisited immunoreactivity between native semi-purified protoplasmic (Caprine) versus commercial purified protoplasmic (Bovine) antigens for the screening of Goatherds endemic for Johne’s disease. Indian J Biotechnol. 16:22–29.

Gupta S, Singh SV, Bhatia AK. 2016. Immuno-reactivity pattern of secretory proteins of Mycobacterium avium subsp. paratuberculosis vaccine strain ‘S 5’ with potential for diagnosis of Johne’s disease in early infection. Indian J Biotech. 15:306–312.

Gwozdz JM, Thompson KG, Manktelow BW, Murray A, West DM. 2000. Vaccination against paratuberculosis of lambs already infected experimentally with Mycobacterium avium subsp. paratuberculosis. Aust Vet J. 78(8):560–566.

Hore DE, McQueen DS, McKinna DA. 1971. Infection of dairy cattle with Mycobacterium Johnei in a partially vaccinated herd. Aust Vet J. 47(9):421–423.

Huntley JF, Stabel JR, Bannantine JP. 2005. Immunoreactivity of the Mycobacterium avium subsp. paratuberculosis 19-kDa lipoprotein. BMC Microbiol. 5:3.

Hurley S, Ewing E. 1983. Results of a field evaluation of a whole cell bacterin. In: Merkal RS, editor. Proceedings of the International Colloquium on Paratuberculosis, I; NADC, USDA, Ames IA, USA; International Association for Paratuberculosis, pp. 244–248.

Jayaraman S, J, MuktaDharma K, Singh SV, Dutta M, Jain N, Chaubey KK, Gupta S, Aseri GK, Khare N, et al. 2016. DIVA technology: indispensable tool for the control of Johnse’s disease. JEBAS. 4(1):16–25.

Jorgensen JB. 1983. The effect of vaccination on the excrion of Mycobacterium paratuberculosis. In: Merkal RS, editor. Proceedings of the International Colloquium on Paratuberculosis, I; NADC, USDA, Ames IA, USA; International Association for Paratuberculosis. p. 249–254.

Joste RA, Geijo MV, Sevilla I, Aduriz G, Garrido JM. 2002. Control of paratuberculosis by vaccination. In: Juste RA, editor. Proceedings of the 7th International Colloquium on Paratuberculosis; Bilbao, Spain: International Association for Paratuberculosis. p. 331.

Kalis CH, Hesselink JW, Barkema HW, Collins MT. 2001. Use of long-term vaccination with a killed vaccine to prevent fecal shedding of Mycobacterium avium subsp paratuberculosis in dairy herds. Am J Vet Res. 62(2):270–274.

Kalis CHJ, Benedictus G, van Weering HJ, Flaman D, Haagsma J. 1992. Experiences with the use of an experimental vaccine in the control of paratuberculosis in The Netherlands. In: Chiodini RJ, Kreeger JM, editors. Proceedings of the 3rd International Colloquium on Paratuberculosis; Providence, RI, USA: International Association for Paratuberculosis, p. 484–494.

Kathapermal K, Kumanan V, McDonough S, Chen LH, Park SU, Moreira MA, Akey B, Huntley J, Chang CF, Chang YF. 2009. Evaluation of immune responses and protective efficacy in a goat model following immunization with a cocktail of recombinant antigens and a polyprotein of Mycobacterium avium subsp. paratuberculosis. Vaccine. 27(1):123–135.

Kirkeby C, Graesebell K, Nielsen SS, Christiansen LE, Toft N, Halasa T. 2016. Adaptive test schemes for control of paratuberculosis in dairy cows. PLoS One. 11(12):e0167219

Klawonn W, Cussler K, Drager KG, Gyra H, Klahn B, Hausleithner D, Cussler K, Klawonn W, Hess RG. 2002. The importance of allergic skin test with Johnin, antibody ELISA, cultural fecal test as well as vaccination for the sanitation of three chronically paratuberculosis-infected dairy herds in Rhineland-Palatinate. DTW Dtsch Tierarztl Wochenschr. 109(12):510–516.

Koets A, Hoek A, Langelaar M, Overdijk M, Santema W, Franken P, Eden W, Rutten V. 2006. Mycobacterial 70 kD heat-shock protein is an effective subunit vaccine against bovine paratuberculosis. Vaccine. 24(14):2550–2559.

Koets AP, Rutten VP, Hoek A, Bakker D, van Zijdeveld F, Muller KE, van Eden W. 1999. Heat-shock protein-specific T-cell responses in various stages of bovine paratuberculosis. Vet Immunol Immunopathol. 70(1-2):105–115.

Kohler H, Gyra H, Zimmer K, Drager KG, Burkert B, Lemser B, Hausleithner D, Cussler K, Klawonn W, Hess RG. 2001. Immune reactions in cattle after immunization with a Mycobacterium paratuberculosis vaccine and implications for the diagnosis of M. paratuberculosis and M. bovis infections. J Vet Med Ser B. 48(3):185–195.

Konboon M, Bani-Yaghoub M, Pithua PQ, Rhee N, Aly SS. 2018. A nested compartmental model to assess the efficacy of paratuberculosis control measures on US dairy farms. PLoS One. 13(10):e0203190.
Kormendy B. 1994. The effect of vaccination on the prevalence of paratuberculosis in large dairy herds. Vet Microbiol. 41:117–125.
Kumar S, Singh SV, Sevilla I, Singh AV, Whittington RJ, Juste RA, Sharma G, Singh PK, Sohal JS. 2008. Lacto-prevalence, genotyping of Mycobacterium avium subspecies paratuberculosis and evaluation of three diagnostic tests in milk of naturally infected Goatherds. Small Rumin Res. 74(1–3):37–44.
Lamont EA, Talatat AM, Coussens PM, Bannantine JP, Grohn YT, Katani R, Li LL, Kapur V, Sreevatsan S. 2014. Screening of Mycobacterium avium subsp. paratuberculosis mutants for attenuation in a bovine monocyte-derived macrophage model. Front Cell Infect Microbiol. 4:87.
Larsen AB, Merkal RS, Moon HW. 1974. Evaluation of a paratuberculosis vaccine given to calves before infection. Am J Vet Res. 35(3):367–369.
Mukartal SY, Rathnamma D, Narayanaswamy HD, Isloor S, Singh S, Chandranak BM, Methuku SR, Elattuvalappil AM, Mallaiash S, Shambanna MS. 2016. Prevalence of Ovine Johne’s disease in Bannur breed of sheep in organized farm using multiple diagnostic tests. Adv Anim Vet Sci. 4:506–512.
Munir MT, Munir AR, Hassan M, Abubakar M. 2014. Epidemiology, diagnosis and control options of Johne’s disease in endemic situations. Res J Vet Pract. 2(5):84–90.
Musken’s J, van Zijderveld F, Eger A, Bakker D. 2002. Evaluation of the long-term immune response in cattle after vaccination against paratuberculosis in two Dutch dairy herds. Vet Microbiol. 86(3):269–278.
NADIS. 2009. National Animal Disease Information Service. Biosecurity in Dairy and Beef Cattle. http://www.nadis.org.uk/disease-a-z/cattle/biosecurity-in-dairy-and-beef-cattle/.
Nagata R, Muneta Y, Yoshihara K, Yokomizo Y, Moti Y. 2005. Expression cloning of gamma interferon-inducing antigens of Mycobacterium avium subsp. paratuberculosis. Infect Immun. 73(6):3778–3782.
Olsen J, Reitan LJ, Holstad G, Wiker HG. 2000. Alkyl hydroperoxide reductases C and D are major antigens constitutively expressed by Mycobacterium avium subsp. paratuberculosis. Infect Immun. 68(2):801–808.
Park HT, Yoo HS. 2016. Development of vaccines to Mycobacterium avium subsp. paratuberculosis infection. Clin Exp Vaccine Res. 5(2):108–116.
Park KT, Allen AJ, Bannantine JP, Seo KS, Hamilton MJ, Abdellrazeq GS, Rihan HM, Grimm A, Davis WC. 2011. Evaluation of two mutants of Mycobacterium avium subsp. paratuberculosis as candidates for a live attenuated vaccine for Johne’s disease. Vaccine. 29(29-30):4709–4719.
Patterson CJ, LaVventure M, Hurley SS, Davis JP. 1988. Accidental self-inoculation with Mycobacterium paratuberculosis bacterin (Johne’s bacterin) by veterinarians in Wisconsin. J Am Vet Med Assoc. 192(9):1197–1199.
Patten EA. 2011. Paratuberculosis vaccination. Vet Clin North Am Food Anim Pract. 27(3):573–580.
Rawat KD, Chaudhary S, Gupta S, Chauhey KK, Jayaraman S, Kumar N, Sohal JS, Sachan TK, Dharma K, Singh SV. 2014. Potential of ‘goat based vaccine’ using ‘India bison biotype’ of Mycobacterium avium subspecies paratuberculosis in salvaging a dairy farm consisting of high yielding Holstein Fresian cows from devastation and closure due to outbreak of bovine Johne’s disease in Northern India. Adv Anim Vet Sci. 2:638–646.
Reddcliff L, Epplleton J, Windsor P, Whittington R, Jones S. 2006. Efficacy of a killed vaccine for the control of paratuberculosis in Australian sheep flocks. Vet Microbiol. 115(1–3):77–90.
Rigden RC, Jandhyala DM, Dupont C, Crosbie-Caird D, Lopez-Villalobos N, Maeda N, Gicquel B, Murray A. 2006. Humoral and cellular immune responses in sheep immunized with a 22 kilodalton exported protein of Mycobacterium avium subspecies paratuberculosis. J Med Microbiol. 55(12):1735–1740.
Rosseels V, Huygen K. 2008. Vaccination against paratuberculosis. Expert Rev Vaccines. 7(6):817–832.
Sanetma W, Rutten V, Koets A. 2011. Bovine paratuberculosis: recent advances in vaccine development. Vet Q. 31(4):183–191.
Saxegaard F, Fodstad FH. 1985. Control of paratuberculosis (Johne’s disease) in goats by vaccination. Vet Rec. 116(16):439–441.
Serrano M, Elguezabal N, Sevilla IA, Geijo MV, Molina E, Arrazuria R, Urtiztke A, Jones GJ, Vordermeier M, Garrido JM, Juste RA. 2017. Tuberculosis detection in paratuberculosis vaccinated calves: new alternatives against interference. PLoS One. 12(1):e0169735.
Sharma G, Singh SV, Sevilla I, Singh AV, Whittington RJ, Juste RA, Kumar S, Gupta VK, Singh PK, Sohal JS, Vihan VS. 2008. Evaluation of indigenous milk ELISA with m-culture and m-PCR for the diagnosis of Bovine Johne’s disease (BJD) in lactating Indian dairy cattle. Res Vet Sci. 84(1):30–37.
Shephard RW, Williams SH, Beckett SD. 2016. Farm economic impacts of bovine Johne’s disease in endemicly infected Australian dairy herds. Aust Vet J. 94: 232–239.
Shin SJ, Chang CF, Chang CD, McDonough SP, Thompson B, Yoo HS, Chang YF. 2005. In vitro cellular immune responses to recombinant antigens of Mycobacterium avium subsp. paratuberculosis. Infect Immun. 73(8):5074–5085.
Shroff S, Chandel BS, Dadawala AI, Singh SV, Bhagat AG, Chauhan HC, Gupta S. 2013. Evaluation of Indigenous vaccine in Panatwadi sheep naturally infected with clinical Johne’s disease. Res OpinAnim Vet Sci. 3:322.
Sigurdsson B. 1960. A killed vaccine against paratuberculosis (Johne’s disease) in sheep. Am J Vet Res. 21:54–67.
Singh AV, Singh SV, Singh PK, Sohal JS. 2010. Genotype diversity in Indian isolates of Mycobacterium avium sub-species paratuberculosis recovered from domestic and wild ruminants from different agro-climatic regions. Comp Immunol Microbiol Infect Dis. 33(6):e127–31.
Singh K, Chandel BS, Chauhan HC, Dadawala A, Singh SV, Singh PK. 2013. Efficacy of ‘Indigenous Vaccine’ using native ‘Indian Bison Type’ genotype of Mycobacterium avium subspecies paratuberculosis for the control of clinical Johne’s disease in an organized goat herd. Vet Res Commun. 37(2):109.
Singh GV, Gupta S, Chauhey KK, Bhusan S, Rawat KD, Kumar N, Tiwari HA, Chaturvedi V, Sohal JS, Dhama K, Hematz. 2017. Therapeutic management of incurable paratuberculosis using ‘Indigenous Vaccine’ in Goatherds, endemically infected with Johne’s disease. Int J Pharmacol. 13:145–155.
Singh GV, Gupta S, Chauhey KK, Kumar N, Rawat KD, Tiwari R, Dhama K. 2014b. Dose standardization studies of ‘indigenous vaccine’ for the control of mycobacterium avium subspecies paratuberculosis in naturally infected goats. Adv Anim Vet Sci. 2:17–23. (IS):
Singh SV, Singh AV, Singh PK, Gupta S, Singh H, Singh B, Kumar ORV, Rajendran AS, Swain NN, Sohal JS. 2013. Evaluation of ‘Indigenous vaccine’ developed using
Stringer LA, Wilson PR, Heuer C, Mackintosh CG. 2013. A randomised controlled trial of Silurium vaccine for control of paratuberculosis in farmed red deer. Vet Rec. 173(22):551.